In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

Lauren Goodman, a registered nurse at Juliana Clinics in Beverly Hills, says she’s had people traveling from around the US to ...

In-office treatments are expensive, time-consuming, and realistically not something most of us can book as often as ...

Even with breakthroughs, treatment for advanced squamous cell carcinoma is more complex. Patients often need more than one treatment. Many patients with this advanced cancer are cared for by a team of ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

According to Jin, the Medicube PDRN Pink Peptide Serum fits flawlessly into any routine. Apply it after your favorite ...

Social media thrives on transformation narratives, and skincare content is no exception. PDRN isn't totally snake oil, but is ...